NLRP3 and inflammatory bowel disease: Taken together, these results indicate that P2X7R and Pannexin-1 may be potential therapeutic targets for the treatment of IBD [57, 58] and that HPM can inhibit the activation of the P2X7R-Pannexin-1 signaling pathway, the upstream pathway of the NLRP3 inflammasome.